The browser doesnot support javascript
Print Plan Forms | Help

Medication Safety Alerts

Zinbryta® Withdrawal

March 22, 2018

On March 22, 2018, Biogen and Abbvie announced a voluntary withdrawal of Zinbryta® from the market. This decision was because of concerns about the drug’s evolving benefit/risk profile. As a result, The United States Food and Drug Administration (FDA) is working closely with the manufacturers to help make sure a well-organized withdrawal from the market in the United States, and to ensure that doctors have the information they need to carefully move their patients using Zinbryta to another medicine to treat their condition.  No new patients will start taking Zinbryta or participate in clinical studies. The company has begun notifying health care professionals and patients, and the drug will be available for patients as needed until April 30, 2018.

Plan members using should not stop taking their medicine without talking with their doctor and should contact their doctor immediately if they have any new and unexplained symptoms.

If you are currently taking Zinbryta and have questions, please call your doctor or call Biogen service center toll-free at 1-800-456-2255 or visit www.zinbryta.com.

You may also call the FDA consumer inquiry line toll-free at 1‑888‑INFO‑FDA (1‑888‑463‑6332) or visit https://www.fda.gov/.

CVS Caremark Response:

Please note: This product is carried by the CVS Specialty Pharmacies only. Because of this action, CVS Specialty is sending letters to members who received this product through CVS Specialty Pharmacies and their physicians.

The CVS/caremark™ app lets you manage your prescription benefits on the go. Download it now:

CVS Health LogoCVS Pharmacy LogoCVS Minute Clinic LogoCVS Specialty LogoSilverscript LogoAccordant Logo

Copyright © 2018 CVS/caremark. All rights reserved| Terms and Conditions | Privacy Policy | Accessibility | Member Rights & Responsibilities